
==== Front
Lipids Health Dis
Lipids Health Dis
Lipids in Health and Disease
1476-511X
BioMed Central London

2269
10.1186/s12944-024-02269-9
Research
Associations between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hyperuricemia: a cross-sectional study
Jiang Zhimeng 13
Zhu Xingyu 12
Zhao Donglin 13
Jiang Huixin 4
Wang Xiaoying 3
Su Feifei sufeifeiBJ2024@163.com

2
1 https://ror.org/03hqwnx39 grid.412026.3 0000 0004 1776 2036 Graduate School of Hebei North University, Zhangjiakou, 075031 Hebei Province China
2 https://ror.org/05tf9r976 grid.488137.1 0000 0001 2267 2324 Department of Cardiovascular Medicine, Air Force Medical Center, Chinese People’s Liberation Army, Beijing, Beijing, 100142 China
3 https://ror.org/05tf9r976 grid.488137.1 0000 0001 2267 2324 Department of Gastroenterology, Air Force Medical Center, Chinese People’s Liberation Army, Beijing, Beijing, 100142 China
4 https://ror.org/038c3w259 grid.285847.4 0000 0000 9588 0960 Graduate School of Kunming, Medical University Haiyuan College, Kunming, 65000 Yunnan Province China
3 9 2024
3 9 2024
2024
23 28018 6 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background and objective

The value of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) assessment in the context of metabolic abnormalities is growing in importance. Nevertheless, the relationship between NHHR and hyperuricemia (HUA) is unknown. This study seeks to investigate the relationship between NHHR and HUA.

Methods

The data derived from the 2017–2020 National Health and Nutrition Examination Survey (NHANES) included 7,876 adult participants. The multivariable logistic regression model, subgroup analysis and smooth fitting curve were utilized in order to investigate the association between NHHR and HUA.

Results

In the fully adjusted model 3, NHHR was significantly associated with HUA. Specifically, participants in the highest quartile of NHHR had 1.95 times higher odds of HUA prevalence compared to those in the lowest quartile [2.95 (2.39, 3.64), P < 0.0001]. Although the overall trend suggested a positive association, further analysis using smooth fitting curves and threshold effect analysis indicated that this association was nonlinear, with an inflection point at 5.8. The positive association persisted across different HUA definitions and after removing outliers. Subgroup analysis showed significant interactions between NHHR and HUA in different races and diabetes statuses. The odds of HUA prevalence were higher among non-diabetic participants [1.40 (1.32, 1.49), P < 0.0001] compared to diabetic participants [1.18 (1.06, 1.32), P = 0.0031]. Mexican Americans had the lowest odds of HUA prevalence [1.09 (0.92, 1.27), P = 0.2413] compared to other races.

Conclusions

There is a significant positive association between NHHR and HUA, indicating that NHHR may serve as a potential risk assessment maker for HUA, although further prospective studies are needed for validation.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12944-024-02269-9.

Keywords

Hyperuricemia
Cross-sectional study
Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio
The Science and Technology Promotion Program of the Chinese People’s Liberation Army Air Force Medical Center and Beijing Natural Science Foundation2022ZTYB14 and 7232174 2022ZTYB14 and 7232174 2022ZTYB14 and 7232174 2022ZTYB14 and 7232174 2022ZTYB14 and 7232174 2022ZTYB14 and 7232174 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Hyperuricemia (HUA) is a metabolic disorder which is characterized by an elevation in the levels of uric acid. The prevalence of HUA is 20% among women and 20.2% among men in the United States. The incidence of HUA has shown an increasing trend globally in recent years [1, 2]. The deposition of uric acid and urate in the human body can result in a number of complications, including as gout, kidney damage, and kidney stones [3, 4]. Increasing evidence suggests that HUA is linked to a wide range of diseases, including chronic kidney disease, metabolic syndrome, and cardiovascular diseases [5–8]. HUA poses a serious threat to human health and quality of life, imposing a substantial economic burden on global public health [9].

Lipid metabolism dysregulation in the body is linked to the onset and progression of various cardiovascular diseases. Moreover, the relationship between uric acid and metabolic syndrome is bidirectional and complex. This complex interplay suggests that uric acid is both a marker and a mediator of metabolic disturbances [10]. Compared to traditional assessments of body lipid indicators, the value of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) assessment in the context of metabolic abnormalities is growing in importance. Studies have shown that NHHR holds significant importance in the research of cardiovascular diseases and metabolic syndrome [11, 12]. Elevated NHHR levels also have significant clinical value in the risk assessment of diseases in particular breast cancer, abdominal aortic aneurysm, depression, and kidney stones [13–16]. Obesity and insulin resistance are becoming global health issues and are also risk factors for HUA. These conditions are inextricably linked to dysregulation of lipid metabolism in the body [17–19]. Dysregulation of lipid metabolism can alter the body’s metabolic patterns and affect disease progression in patients with HUA [20, 21]. However, the relationship between NHHR, as a novel lipid indicator, and HUA remains unclear.

Therefore, we utilized sample data from the National Health and Nutrition Examination Survey (NHANES) of American adults to investigate the association between NHHR and HUA. This study may provide a novel insight into the pathogenesis of HUA for future research.

Methods

Study population

NHANES, a significant epidemiological survey project led by the National Center for Health Statistics (NCHS), is for the purpose of evaluating the health and nutrition of Americans, Providing critical data on the health status of Americans to policymakers, researchers, and the public [22]. From the 15,560 participants in NHANES 2017–2020, we excluded 6,373 participants who lacked serum uric acid data and were under 18 years of age, and 1,311 participants who lacked NHHR data. Ultimately, 7,876 participants who met the study criteria were included (Fig. 1).

Fig. 1 Flow chart of participants selection

Definition of outcome and exposure variables

The outcome variable in this study is HUA, which is diagnosed based on serum uric acid levels. HUA is diagnosed when a serum uric acid concentration reaches a level of ≥ 6 mg/dL in females and ≥ 7 mg/dL in males [23]. Sensitivity analysis was conducted using different definitions of HUA, including serum uric acid concentration ≥ 6.8 mg/dL [24], to ensure the robustness of the study findings. Serum uric acid levels were measured by professionals using the Roche Cobas 6000 analyzer (c501 module).

The exposure variable is NHHR. This is calculated by dividing non-high-density lipoprotein cholesterol (total cholesterol minus high-density lipoprotein cholesterol) by high-density lipoprotein cholesterol [25].

Covariables

To more accurately understand the relationship between HUA and NHHR, We included potential confounding covariables including demographic factors (gender, race, age, education level, family income-to-poverty ratio (PIR), marital status), lifestyle factors (physical activity status, drink status, smoking status), clinical measurements (glycated hemoglobin, total bilirubin, fasting blood glucose, serum creatinine, urinary albumin, serum urea nitrogen, aspartate aminotransferase, alanine aminotransferase, waist circumference, body mass index (BMI), systolic and diastolic blood pressure and medical history (diabetes, hyperlipidemia, high blood pressure, and kidney stones). The definitions of these covariables can be found in Supplementary Table 1. Missing values for covariables are replaced by medians for continuous variables and plurals for categorical variables.

Statistical analysis

All statistical analyses were performed using Empower software (www.empowerstats.com) and R version 4.1.3. The appropriate NHANES sampling weights, as prescribed in the guidelines established by the Centers for Disease Control and Prevention (CDC), were duly applied. In the case of continuous data variables, variance-weighted analysis was employed, while in the case of categorical variables, weighted chi-square tests were used to assess differences between NHHR quartiles. In constructing multivariable analyses, we employed three different models to evaluate the association between NHHR and HUA. Model 1 is not adjusted to account for any variables. Model 2 was adjusted for demographic factors (including race, age, and gender). Model 3 incorporated all covariable adjustments. To deal with potential outliers in the NHHR distribution, we examined the data for abnormal truncated tail values. Outliers were defined as values greater than three standard deviations from the mean. These outliers were removed and the analyses repeated to assess the robustness of the association between NHHR and HUA. We performed linear trend tests by converting NHHR levels into quartile categorical variables. To examine the nonlinear relationship and inflection points between NHHR and HUA, a smooth fitting curve and threshold effect analysis were utilised. Finally, subgroup analyses were performed to identify any statistically significant differences between the various subgroups, including race, gender, age, BMI, diabetes, high blood pressure and estimated glomerular filtration rate (eGFR). We decided that the p-value of less than 0.05 was statistically significant.

Results

Baseline characteristics

The weighted distributions of all clinical characteristics for participants are shown in Table 1 across the quartiles of the NHHR. This study included 7,876 adults with an mean age of 48.43 ± 17.32 years. The study population consisted of 48.29% male and 51.71% female participants. The mean NHHR was 2.72 ± 1.23, and the NHHR range for the 1st to 4th quartiles was 0.28–1.80, 1.80–2.50, 2.50–3.35, and 3.35–11.9, respectively. The overall prevalence of HUA was 17.28%, with quartile-specific prevalence rates of 10.96% in the 1st quartile, 12.75% in the 2nd quartile, 19.29% in the 3rd quartile, and 25.78% in the 4th quartile. Significant differences were observed across NHHR quartiles in terms of race, gender, age, drink status, glycated hemoglobin, systolic and diastolic blood pressure, fasting blood glucose, PIR, education level, marital status, smoking status, serum creatinine, urinary albumin, aspartate aminotransferase, total bilirubin, alanine aminotransferase, and the prevalence of diabetes, hyperlipidemia, high blood pressure, kidney stones, and HUA (p < 0.05).

Table 1 Baseline characteristics of the study population

Quartiles of NHHR	
Characteristic	Q1 (0.28–1.80)
N = 1967	Q2 (1.80–2.50)
N = 1971	Q3 (2.50–3.35)
N = 1969	Q4 (3.35–11.9)
N = 1969	P- value	
Age (years)	47.89 ± 19.35	49.24 ± 17.88	49.58 ± 16.45	47.02 ± 15.30	< 0.0001	
Ratio of family income to poverty	3.23 (1.78 ,5.00)	3.22 (1.79 ,5.00)	2.92 (1.58 ,4.81)	3.08 (1.73 ,5.00)	0.0133	
Glycohemoglobin (%)	5.40 (5.10 ,5.70)	5.50 (5.20 ,5.80)	5.50 (5.30 ,5.90)	5.60 (5.30 ,5.90)	< 0.0001	
Fasting glucose (mg/dL)	99.00 (92.00 ,107.00)	101.10 (95.00 ,110.00)	104.00 (97.00 ,113.00)	107.19 (100.00 ,118.00)	< 0.0001	
Alanine aminotransferase (U/L)	19.00 (16.00 ,23.00)	19.00 (16.00 ,23.00)	19.00 (16.00 ,24.00)	20.00 (16.00 ,25.00)	0.0169	
Aspartate aminotransferase (U/L)	15.00 (12.00 ,21.00)	17.00 (13.00 ,24.00)	18.00 (14.00 ,27.00)	22.00 (16.00 ,32.00)	< 0.0001	
Total bilirubin (mg/dL)	0.40 (0.30 ,0.60)	0.40 (0.30 ,0.60)	0.40 (0.30 ,0.60)	0.40 (0.30 ,0.50)	0.0014	
Serum creatinine (mg/dL)	0.80 (0.69 ,0.94)	0.82 (0.70 ,0.97)	0.85 (0.72 ,1.00)	0.88 (0.76 ,1.01)	0.0088	
Blood urea nitrogen (mg/dL)	14.00 (11.00 ,18.00)	14.00 (11.00 ,17.00)	14.00 (12.00 ,18.00)	14.00 (12.00 ,17.00)	0.8585	
Systolic pressure(mmHg)	120.76 ± 18.62	122.38 ± 17.78	121.99 ± 16.57	123.06 ± 16.35	0.0004	
Diastolic pressure(mmHg)	71.56 ± 10.62	73.67 ± 10.79	74.82 ± 10.32	76.97 ± 10.44	< 0.0001	
Waist circumference (cm)	89.44 (77.30 ,101.70)	89.41 (74.70 ,101.70)	89.74 (77.30 ,104.00)	89.53 (74.10 ,102.20)	0.5943	
Albumin, urine (ug/mL)	8.00 (4.20 ,16.00)	7.30 (3.60 ,15.50)	8.30 (4.30 ,15.90)	8.80 (4.40 ,18.00)	0.1551	
Body mass index(kg/m2)	26.47 (22.00 ,30.10)	26.33 (20.60 ,30.20)	26.42 (21.60 ,30.30)	26.40 (21.10 ,29.60)	0.6677	
eGFR (ml/min/1.73 m2)	103.89 ± 24.36	100.88 ± 22.20	98.94 ± 21.97	98.82 ± 21.87	< 0.0001	
Gender (%)					< 0.0001	
Male	727 (33.69)	846 (41.59)	979 (51.63)	1255 (65.53)		
Female	1240 (66.31)	1125 (58.41)	990 (48.37)	714 (34.47)		
Race (%)					< 0.0001	
Mexican American	176 (6.68)	206 (7.31)	260 (9.21)	305 (10.73)		
Other Hispanic	154 (6.56)	210 (7.36)	210 (7.57)	257 (9.11)		
Non-Hispanic White	683 (63.97)	721 (64.44)	688 (62.76)	685 (61.83)		
Non-Hispanic Black	649 (14.52)	527 (11.47)	468 (9.80)	358 (7.43)		
Other Race	305 (8.26)	307 (9.41)	343 (10.67)	364 (10.90)		
Education level (%)					< 0.0001	
Less than high school	298 (8.02)	325 (10.29)	397 (11.70)	459 (13.94)		
High school	492 (25.39)	459 (24.91)	479 (28.80)	467 (28.61)		
More than high school	1177 (66.60)	1187 (64.79)	1093 (59.50)	1043 (57.45)		
Marriage (%)					< 0.0001	
Yes	1023 (57.58)	1128 (59.61)	1179 (63.41)	1234 (67.44)		
No	944 (42.42)	843 (40.39)	790 (36.59)	735 (32.56)		
Smoking (%)					< 0.0001	
Yes	806 (39.67)	769 (41.72)	818 (40.97)	905 (48.64)		
No	1161 (60.33)	1202 (58.28)	1151 (59.03)	1064 (51.36)		
Drink (%)					< 0.0001	
Yes	294 (12.14)	280 (12.47)	317 (14.35)	330 (16.77)		
No	1161 (87.86)	1691 (87.53)	1625 (85.65)	1639 (83.23)		
Moderate work activity (%)					0.5429	
Yes	876 (48.49)	844 (49.48)	835 (47.54)	894 (49.54)		
No	1091 (51.51)	1127 (50.52)	1134 (52.46)	1075 (50.46)		
High blood pressure (%)					0.0001	
Yes	744 (28.97)	750 (31.90)	775 (34.67)	768 (34.99)		
No	1223 (71.03)	1221 (68.10)	1194 (65.33)	1201 (65.01)		
Diabetes (%)					0.0278	
Yes	287 (10.71)	298 (10.43)	319 (13.10)	316 (12.19)		
No	1680 (89.29)	1673 (89.57)	1650 (86.90)	1653 (87.81)		
Hypertriglyceridemia (%)					< 0.0001	
Yes	558 (24.85)	678 (33.36)	715 (35.29)	876 (44.86)		
No	1409 (75.15)	1293 (66.64)	1254 (64.71)	1093 (55.14)		
kidney stone (%)					0.0035	
Yes	150 (8.32)	177 (9.54)	218 (11.73)	206 (10.57)		
No	1817 (91.68)	1794 (90.46)	1751 (88.27)	1763 (89.43)		
Hyperuricaemia (%)					< 0.0001	
Yes	249 (10.96)	289 (12.75)	407 (19.29)	516 (25.78)		
No	1718 (89.04)	1682 (87.25)	1562 (80.71)	1453 (74.22)		
Mean ± standard deviation for normally distributed continuous variables, median and interquartile range for non-normally distributed continuous variables: the P value was calculated by the weighted linear regression model; (%) for categorical variables: the P value was calculated by the weighted chi-square test, n = unweighted sample size; % = weighted percentage. Abbreviation: NHHR, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio; eGFR, estimated glomerular filtration rate

Elevated NHHR levels are linked to a higher odds of HUA Prevalence

Table 2 shows a positive association between NHHR and HUA across all three models, all of which were statistically significant. When NHHR was treated as a quartile variable, the highest quartile of NHHR participants exhibited a 1.95 times greater odds of HUA prevalence compared to the lowest quartile [2.95 (2.39, 3.64), P < 0.0001]. When different definitions of HUA were used, this similar association has also been observed in this instance. The results of Supplementary Table 2 indicate that this positive association remained statistically significant even after the exclusion of the outliers. The findings of the smooth fitting curve showed a nonlinear relationship between NHHR and HUA (Fig. 2). Table 3 indicates that the inflection points for NHHR and HUA were 5.8.

Fig. 2 The nonlinear associations between NHHR and hyperuricemia

Table 2 Associations between NHHR and hyperuricemia

Characteristic	Model 1 OR (95%CI)
N = 7876	Model 2 OR (95%CI)
N = 7876	Model 3 OR (95%CI)
N = 7876	
Primary Definition (≥ 6/7 mg/dL)				
NHHR	1.28 (1.22, 1.33)	1.33 (1.27, 1.40)	1.36 (1.28, 1.44)	
Categories				
Q1	1.0	1.0	1.0	
Q2	1.19 (0.99, 1.42)	1.22 (1.02, 1.47)	1.25 (1.03, 1.52)	
Q3	1.80 (1.51, 2.14)	1.92 (1.61, 2.28)	2.01 (1.66, 2.44)	
Q4	2.45 (2.07, 2.89)	2.82 (2.37, 3.36)	2.95 (2.39, 3.64)	
NHHR group trend	1.42 (1.34, 1.51) < 0.0001	1.50 (1.41, 1.60) < 0.0001	1.52 (1.41, 1.64) < 0.0001	
Alternative Definition (≥ 6.8 mg/dL)				
NHHR	1.21 (1.16, 1.27)	1.19 (1.13, 1.24)	1.20 (1.14, 1.26)	
Categories				
Q1	1.0	1.0	1.0	
Q2	1.08 (0.90, 1.29)	1.06 (0.89, 1.27)	1.10 (0.92, 1.32)	
Q3	1.44 (1.21, 1.71)	1.38 (1.16, 1.64)	1.46 (1.22, 1.75)	
Q4	1.87 (1.59, 2.21)	1.73 (1.46, 2.05)	1.79 (1.49, 2.16)	
NHHR group trend	1.29 (1.21, 1.36) < 0.0001	1.25 (1.17, 1.33) < 0.0001	1.26 (1.18, 1.35) < 0.0001	
Model 1: no covariables were adjusted. Model 2: age, gender, and race were adjusted. Model 3: gender, age, race, family income-to-poverty ratio, education level, physical activity status, marital status, drink status, smoking status, systolic blood pressure, diastolic blood pressure, glycated hemoglobin, total bilirubin, fasting blood glucose, serum creatinine, serum urea nitrogen, urinary albumin, aspartate aminotransferase, alanine aminotransferase, body mass index, waist circumference, and history of diabetes, high blood pressure, hyperlipidemia, and kidney stones were adjusted. Abbreviation: NHHR, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

Table 3 Threshold effect analysis of NHHR on hyperuricemia using a two-piecewise linear regression model

Model	OR (95%CI)	P- value	
Inflection point (K)	5.8		
Fitting by two-piecewise linear model			
NHHR ≤ 5.8	1.44 (1.36, 1.52)	< 0.0001	
NHHR > 5.8	0.69 (0.52,0.91)	0.0102	
Log-likelihood ratio		< 0.001	
gender, age, race, family income-to-poverty ratio, education level, physical activity status, marital status, drink status, smoking status, systolic blood pressure, diastolic blood pressure, glycated hemoglobin, total bilirubin, fasting blood glucose, serum creatinine, serum urea nitrogen, urinary albumin, aspartate aminotransferase, alanine aminotransferase, body mass index, waist circumference, and history of diabetes, high blood pressure, hyperlipidemia, and kidney stones were adjusted. Abbreviation: NHHR, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

Subgroup analysis

Table 4 shows the different associations between NHHR and HUA across various subgroups. A positive association between NHHR and HUA was identified in each subgroup. Additionally, we observed significant interactions between NHHR and HUA in the race and diabetes subgroups (p < 0.05). The odds of HUA prevalence were higher among non-diabetic participants [1.40 (1.32, 1.49), P < 0.0001] compared to diabetic participants [1.18 (1.06, 1.32), P = 0.0031]. Among the different races, Mexican Americans had the lowest odds of HUA prevalence [1.09 (0.92, 1.27), P = 0.2413] compared to other races.

Table 4 Subgroup analysis of the association between NHHR and hyperuricemia

Characteristic	Model OR (95%CI)	P- value	P for interaction	
Stratified by age (years)			0.0548	
20–40	1.54 (1.40, 1.69)	< 0.0001		
40–60	1.27 (1.17, 1.38)	< 0.0001		
60–80	1.32 (1.21, 1.44)	< 0.0001		
Stratified by gender			0.9568	
Male	1.36 (1.27, 1.46)	< 0.0001		
Female	1.36 (1.25, 1.47)	< 0.0001		
Stratified by race			0.0247	
Mexican American	1.09 (0.94, 1.27)	0.2413		
Other Hispanic	1.44 (1.24, 1.66)	< 0.0001		
Non-Hispanic White	1.40 (1.28, 1.53)	< 0.0001		
Non-Hispanic Black	1.40 (1.27, 1.55)	< 0.0001		
Other Race	1.37 (1.22, 1.53)	< 0.0001		
Stratified by BMI			0.6434	
Normal weight	1.37 (1.26, 1.48)	< 0.0001		
Overweight	1.32 (1.21, 1.44)	< 0.0001		
Obese	1.39 (1.27, 1.53)	< 0.0001		
Stratified by Diabetes			0.0031	
Yes	1.18 (1.06, 1.32)	0.0031		
No	1.40 (1.32, 1.49)	< 0.0001		
Stratified by High blood pressure			0.1741	
Yes	1.31 (1.21, 1.41)	< 0.0001		
No	1.40 (1.30, 1.50)	< 0.0001		
Stratified by eGFR			0.0847	
eGFR ≥ 90	1.49 (1.27, 1.74)	< 0.0001		
90< eGFR ≥ 60	1.25 (1.16, 1.36)	< 0.0001		
eGFR<60	1.37 (1.28, 1.46)	< 0.0001		
gender, age, race, family income-to-poverty ratio, education level, physical activity status, marital status, drink status, smoking status, systolic blood pressure, diastolic blood pressure, glycated hemoglobin, total bilirubin, fasting blood glucose, serum creatinine, serum urea nitrogen, urinary albumin, aspartate aminotransferase, alanine aminotransferase, body mass index, waist circumference, and history of diabetes, High blood pressure, hyperlipidemia, and kidney stones were adjusted. Abbreviation: NHHR, non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, BMI, body mass index, eGFR, estimated glomerular filtration rate

Discussion

In this study of 7,876 U.S. adults, the results demonstrated the positive association between NHHR and the odds of HUA prevalence, which persisted across three different models. This remains the case even when different HUA definitions are employed and outliers are removed. The results of the smooth fitting curve indicated a nonlinear positive association between NHHR and HUA. The threshold effect analysis showed an inflection point at 5.8. Furthermore, subgroup analysis revealed significant interactions between different races, diabetes status, and NHHR levels, affecting the odds of HUA prevalence.

HUA is associated with the onset and development of various chronic diseases and has become a significant health issue that cannot be ignored, imposing a heavy burden on public health [1, 5, 26, 27]. The relationship between uric acid and metabolic syndrome is bidirectional and complex; elevated uric acid levels are not only a consequence of metabolic syndrome but can also exacerbate its components, such as insulin resistance, obesity, and lipid metabolism dysregulation. Conversely, insulin resistance can increase uric acid reabsorption in the kidneys, further elevating uric acid levels [10]. Therefore, identifying risk factors for HUA is crucial for guiding clinical prevention and treatment. Increasing research indicates that lipid metabolism is vital in the development of HUA. A study carried out in Northwest China showed that dyslipidemia increases the odds of HUA prevalence, with higher triglyceride levels and total cholesterol levels identified as risk factors for HUA [28]. A retrospective study involving 3,884 subjects found that triglycerides are risk factor for HUA. Individuals with hypertriglyceridemia have a 2.353 times higher odds of HUA prevalence compared to those with normal triglyceride levels [29]. A large-scale cohort study conducted in China by Liu et al [30], over a period of four years involving 15,198 subjects demonstrated that a higher triglyceride to high-density lipoprotein cholesterol ratio is positively correlated with the odds of HUA prevalence. Another study also showed a positive association between residual cholesterol and HUA in Americans, which is similar to what we found, but the association was stronger in those without diabetes [31].

NHHR, as a newly developed lipid indicator, has been shown to have significant predictive value for the risk of kidney stones and diabetes [15, 32]. An elevated NHHR indicates dysregulation of lipid metabolism. The pathogenesis between NHHR and HUA remains unclear. Our study results suggest that elevated NHHR levels are positively associated with the odds of HUA prevalence. Based on existing studies, we propose several possible theoretical explanations: (1) Elevated lipid metabolism levels are closely related to insulin resistance [33, 34]. Insulin resistance is associated with increased expression of Urate transporter 1, which promotes uric acid reabsorption and inhibits the function of adenosine triphosphate-binding cassette subfamily G member 2, reducing uric acid excretion [35], this consequently resulted in elevated serum uric acid levels. Anti-diabetic medications such as pioglitazone and metformin, which improve insulin resistance, can reduce serum uric acid levels [36, 37]. (2) Low serum high-density lipoprotein cholesterol (HDL-C) levels can lead to decreased glomerular filtration function, thereby increasing serum uric acid levels. Low serum HDL-C levels are key factors in atherosclerosis and are major causes of renal artery stenosis and decreased glomerular filtration function [38]. A body of evidence indicates that a low serum HDL-C level represents a risk factor associated with the advancement of chronic kidney disease [39]. (3) High triglyceride levels can lead to increased oxidation of free fatty acids, producing more acetyl-CoA. The liver utilizes free fatty acids to synthesize more purines, resulting in elevated uric acid levels [40]. (4) HDL-C has anti-inflammatory properties. Low levels of HDL-C can weaken antioxidant and anti-inflammatory effects [41]. Low levels of HDL-C trigger inflammatory responses and oxidative stress in the body, promoting purine metabolism and increasing uric acid production [40, 42]. Therefore, we have reason to infer that elevated NHHR levels are associated with HUA.

In the diabetes subgroup of this study, we found that among participants with different NHHR levels, non-diabetic participants had a higher odds of HUA prevalence compared to diabetic participants. This may be because non-diabetic participants might have higher insulin resistance, whereas diabetic patients receive medication to control blood glucose and insulin levels and are often treated with lipid-lowering drugs. Some glucose-controlling and lipid-lowering medications have been shown to reduce serum uric acid levels [36, 37, 43]. Recent studies have highlighted Sodium-Glucose Co-Transporter 2 inhibitors facilitate increased renal excretion of uric acid by inhibiting its reabsorption in the renal proximal tubules [44, 45]. We also found that among participants with different NHHR levels, a lower odds of HUA prevalence was observed in Mexican Americans compared to other racial groups. This may be due to genetic factors, dietary habits, and lifestyle differences [46].

The strengths of our study include utilizing NHANES data, overseen by the CDC, which ensures the rigour and authenticity of the data through a nationally representative survey methodology. Admittedly, our study has certain limitations. Since our study design is cross-sectional, we cannot accurately infer the causal relationship between NHHR and HUA. Although we included many confounding factors that influence NHHR and HUA, there are still some potential confounders that we could not include, such as genetic factors, the use of glucose-controlling and lipid-lowering medications, and the consumption of high-purine foods.

Conclusion

The study results indicate that higher NHHR levels are positively associated with the odds of HUA prevalence, especially when NHHR levels are below the inflection point of 5.8. Early intervention and treatment for individuals with specific NHHR levels may reduce the occurrence of HUA and related complications. Based on these findings, NHHR is expected to become a new indicator for assessing lipid levels in HUA, providing new insights into the link between lipid metabolism disorders and the formation of HUA. Consequently, to substantiate these findings, large-scale prospective studies are required.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

We would like to thank all participants in this study.

Author contributions

ZJ, XZ, and FS designed the research. ZJ, XZ, HJ, XW, and DZ collected, analyzed the data, and drafted the manuscript. ZJ and FS revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by The Science and Technology Promotion Program of the Chinese People’s Liberation Army Air Force Medical Center (2022ZTYB14) and Beijing Natural Science Foundation (7232174).

Data availability

The survey data are publicly available on the internet for data users and researchers throughout the world ( www.cdc.gov/nchs/nhanes/ ).

Declarations

Ethics approval and consent to participate

The portions of this study involving human participants, human materials, or human data were conducted in accordance with the Declaration of Helsinki and were approved by the NCHS Ethics Review Board. The patients/participants provided their written informed consent to participate in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

HUA Hyperuricemia

NHHR Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio

NHANES National Health and Nutrition Examination Survey

NCHS National Center for Health Statistics

CDC Centers for Disease Control and Prevention

PIR Family income-to-poverty ratio

BMI Body Mass Index

HDL-C High-density lipoprotein cholesterol

eGFR Estimated glomerular filtration rate

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Chen-Xu M Yokose C Rai SK Pillinger MH Choi HK Contemporary prevalence of gout and Hyperuricemia in the United States and Decadal trends: the National Health and Nutrition Examination Survey, 2007–2016 Arthritis Rheumatol 2019 71 991 9 10.1002/art.40807 30618180
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and Hyperuricemia in the United States and Decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71:991–9.30618180 10.1002/art.40807
2. Liu R, Han C, Wu D, Xia X, Gu J, Guan H, Shan Z, Teng W. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int 2015, 2015:762820.
3. Xu Z Yao X Duan C Liu H Xu H Metabolic changes in kidney stone disease Front Immunol 2023 14 1142207 10.3389/fimmu.2023.1142207 37228601
Xu Z, Yao X, Duan C, Liu H, Xu H. Metabolic changes in kidney stone disease. Front Immunol. 2023;14:1142207.37228601 10.3389/fimmu.2023.1142207
4. Su HY, Yang C, Liang D, Liu HF. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. Biomed Res Int 2020, 2020:5817348.
5. Shu J Zhao R Xu H Liu X Guo H Lu C Hyperuricemia is associated with metabolic syndrome: a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) Prev Med Rep 2023 36 102520 10.1016/j.pmedr.2023.102520 38116281
Shu J, Zhao R, Xu H, Liu X, Guo H, Lu C. Hyperuricemia is associated with metabolic syndrome: a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES). Prev Med Rep. 2023;36:102520.38116281 10.1016/j.pmedr.2023.102520
6. Han Y Cao Y Han X Di H Yin Y Wu J Zhang Y Zeng X Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey J Transl Med 2023 21 463 10.1186/s12967-023-04307-z 37438830
Han Y, Cao Y, Han X, Di H, Yin Y, Wu J, Zhang Y, Zeng X. Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey. J Transl Med. 2023;21:463.37438830 10.1186/s12967-023-04307-z
7. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical understanding of the pathophysiology and treatments of Hyperuricemia and its Association with Metabolic Syndrome, Cardiovascular diseases and chronic kidney disease. Int J Mol Sci 2021, 22.
8. Kim SY Guevara JP Kim KM Choi HK Heitjan DF Albert DA Hyperuricemia and coronary heart disease: a systematic review and meta-analysis Arthritis Care Res (Hoboken) 2010 62 170 80 10.1002/acr.20065 20191515
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62:170–80.20191515 10.1002/acr.20065
9. Jeong YJ Park S Yon DK Lee SW Tizaoui K Koyanagi A Jacob L Kostev K Dragioti E Radua J Global burden of gout in 1990–2019: a systematic analysis of the Global Burden of Disease study 2019 Eur J Clin Invest 2023 53 e13937 10.1111/eci.13937 36511834
Jeong YJ, Park S, Yon DK, Lee SW, Tizaoui K, Koyanagi A, Jacob L, Kostev K, Dragioti E, Radua J, et al. Global burden of gout in 1990–2019: a systematic analysis of the Global Burden of Disease study 2019. Eur J Clin Invest. 2023;53:e13937.36511834 10.1111/eci.13937
10. Borghi C Fogacci F Piani F Not all the eggs and the chickens are the same: the case of uric acid and metabolic syndrome Eur J Intern Med 2022 103 36 7 10.1016/j.ejim.2022.07.006 35868913
Borghi C, Fogacci F, Piani F. Not all the eggs and the chickens are the same: the case of uric acid and metabolic syndrome. Eur J Intern Med. 2022;103:36–7.35868913 10.1016/j.ejim.2022.07.006
11. Kim SW Jee JH Kim HJ Jin SM Suh S Bae JC Kim SW Chung JH Min YK Lee MS Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1 Int J Cardiol 2013 168 2678 83 10.1016/j.ijcard.2013.03.027 23545148
Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC, Kim SW, Chung JH, Min YK, Lee MS, et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol. 2013;168:2678–83.23545148 10.1016/j.ijcard.2013.03.027
12. Zhu L Lu Z Zhu L Ouyang X Yang Y He W Feng Y Yi F Song Y Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people Kardiol Pol 2015 73 931 8 10.5603/KP.a2015.0086 25985729
Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, Feng Y, Yi F, Song Y. Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. Kardiol Pol. 2015;73:931–8.25985729 10.5603/KP.a2015.0086
13. Luo X, Ye J, Xiao T, Yi T. Exploration of the association of a lipid-related biomarker, the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR), and the risk of breast cancer in American women aged 20 years and older. Int J Surg 2024.
14. Lin W Luo S Li W Liu J Zhou T Yang F Zhou D Liu Y Huang W Feng Y Luo J Association between the non-HDL-cholesterol to HDL- cholesterol ratio and abdominal aortic aneurysm from a Chinese screening program Lipids Health Dis 2023 22 187 10.1186/s12944-023-01939-4 37932803
Lin W, Luo S, Li W, Liu J, Zhou T, Yang F, Zhou D, Liu Y, Huang W, Feng Y, Luo J. Association between the non-HDL-cholesterol to HDL- cholesterol ratio and abdominal aortic aneurysm from a Chinese screening program. Lipids Health Dis. 2023;22:187.37932803 10.1186/s12944-023-01939-4
15. Hong H He Y Gong Z Feng J Qu Y The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stones: a cross-sectional study Lipids Health Dis 2024 23 102 10.1186/s12944-024-02089-x 38615008
Hong H, He Y, Gong Z, Feng J, Qu Y. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stones: a cross-sectional study. Lipids Health Dis. 2024;23:102.38615008 10.1186/s12944-024-02089-x
16. Qi X Wang S Huang Q Chen X Qiu L Ouyang K Chen Y The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and risk of depression among US adults: a cross-sectional NHANES study J Affect Disord 2024 344 451 7 10.1016/j.jad.2023.10.064 37838268
Qi X, Wang S, Huang Q, Chen X, Qiu L, Ouyang K, Chen Y. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and risk of depression among US adults: a cross-sectional NHANES study. J Affect Disord. 2024;344:451–7.37838268 10.1016/j.jad.2023.10.064
17. Kuwabara M, Kuwabara R, Niwa K, Hisatome I, Smits G, Roncal-Jimenez CA, MacLean PS, Yracheta JM, Ohno M, Lanaspa MA et al. Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects. Nutrients 2018, 10.
18. Han Y, Zhou Z, Zhang Y, Zhao G, Xu B. The Association of Surrogates of Insulin Resistance with hyperuricemia among middle-aged and older individuals: a Population-based Nationwide Cohort Study. Nutrients 2023, 15.
19. Peng TC, Wang CC, Kao TW, Chan JY, Yang YH, Chang YW, Chen WL. Relationship between hyperuricemia and lipid profiles in US adults. Biomed Res Int 2015, 2015:127596.
20. Ma L Wang J Ma L Ge Y Wang XM The effect of lipid metabolism disorder on patients with hyperuricemia using Multi-omics analysis Sci Rep 2023 13 18211 10.1038/s41598-023-45564-8 37875599
Ma L, Wang J, Ma L, Ge Y, Wang XM. The effect of lipid metabolism disorder on patients with hyperuricemia using Multi-omics analysis. Sci Rep. 2023;13:18211.37875599 10.1038/s41598-023-45564-8
21. Kvasnička A Friedecký D Brumarová R Pavlíková M Pavelcová K Mašínová J Hasíková L Závada J Pavelka K Ješina P Stibůrková B Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment Arthritis Res Ther 2023 25 234 10.1186/s13075-023-03204-6 38042879
Kvasnička A, Friedecký D, Brumarová R, Pavlíková M, Pavelcová K, Mašínová J, Hasíková L, Závada J, Pavelka K, Ješina P, Stibůrková B. Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment. Arthritis Res Ther. 2023;25:234.38042879 10.1186/s13075-023-03204-6
22. Curtin LR, Mohadjer LK, Dohrmann SM, Kruszon-Moran D, Mirel LB, Carroll MD, Hirsch R, Burt VL, Johnson CL. National Health and Nutrition Examination Survey: sample design, 2007–2010. Vital Health Stat 2 2013:1–23.
23. Johnson RJ Bakris GL Borghi C Chonchol MB Feldman D Lanaspa MA Merriman TR Moe OW Mount DB Sanchez Lozada LG Hyperuricemia, Acute and chronic kidney Disease, Hypertension, and Cardiovascular Disease: report of a Scientific Workshop Organized by the National Kidney Foundation Am J Kidney Dis 2018 71 851 65 10.1053/j.ajkd.2017.12.009 29496260
Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, et al. Hyperuricemia, Acute and chronic kidney Disease, Hypertension, and Cardiovascular Disease: report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851–65.29496260 10.1053/j.ajkd.2017.12.009
24. Bjornstad P Laffel L Lynch J El Ghormli L Weinstock RS Tollefsen SE Nadeau KJ Elevated serum uric acid is Associated with Greater Risk for Hypertension and Diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the Treatment options for type 2 diabetes in adolescents and youth (TODAY) study Diabetes Care 2019 42 1120 8 10.2337/dc18-2147 30967435
Bjornstad P, Laffel L, Lynch J, El Ghormli L, Weinstock RS, Tollefsen SE, Nadeau KJ. Elevated serum uric acid is Associated with Greater Risk for Hypertension and Diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the Treatment options for type 2 diabetes in adolescents and youth (TODAY) study. Diabetes Care. 2019;42:1120–8.30967435 10.2337/dc18-2147
25. Wang A Li Y Zhou L Liu K Li S Zong C Song B Gao Y Li Y Tian C Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: a cross-sectional study Front Neurol 2022 13 875134 10.3389/fneur.2022.875134 36188405
Wang A, Li Y, Zhou L, Liu K, Li S, Zong C, Song B, Gao Y, Li Y, Tian C, et al. Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population: a cross-sectional study. Front Neurol. 2022;13:875134.36188405 10.3389/fneur.2022.875134
26. Yin Y Zhou E Wu J Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001–2018 Front Cardiovasc Med 2024 11 1306026 10.3389/fcvm.2024.1306026 38380182
Yin Y, Zhou E, Wu J. Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001–2018. Front Cardiovasc Med. 2024;11:1306026.38380182 10.3389/fcvm.2024.1306026
27. Jiang J Zhang T Liu Y Chang Q Zhao Y Guo C Xia Y Prevalence of diabetes in patients with hyperuricemia and gout: a systematic review and Meta-analysis Curr Diab Rep 2023 23 103 17 10.1007/s11892-023-01506-2 37099085
Jiang J, Zhang T, Liu Y, Chang Q, Zhao Y, Guo C, Xia Y. Prevalence of diabetes in patients with hyperuricemia and gout: a systematic review and Meta-analysis. Curr Diab Rep. 2023;23:103–17.37099085 10.1007/s11892-023-01506-2
28. Liu F Du GL Song N Ma YT Li XM Gao XM Yang YN Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008–2012) Lipids Health Dis 2020 19 58 10.1186/s12944-020-01211-z 32238146
Liu F, Du GL, Song N, Ma YT, Li XM, Gao XM, Yang YN. Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008–2012). Lipids Health Dis. 2020;19:58.32238146 10.1186/s12944-020-01211-z
29. Hou YL Yang XL Wang CX Zhi LX Yang MJ You CG Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents Lipids Health Dis 2019 18 81 10.1186/s12944-019-1031-6 30935401
Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019;18:81.30935401 10.1186/s12944-019-1031-6
30. Liu XY Wu QY Chen ZH Yan GY Lu Y Dai HJ Li Y Yang PT Yuan H Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China Endocrine 2020 68 71 80 10.1007/s12020-019-02176-5 31940133
Liu XY, Wu QY, Chen ZH, Yan GY, Lu Y, Dai HJ, Li Y, Yang PT, Yuan H. Elevated triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China. Endocrine. 2020;68:71–80.31940133 10.1007/s12020-019-02176-5
31. Zhou X Weng X Xu J Wang W Correlation between remnant cholesterol and hyperuricemia in American adults Lipids Health Dis 2024 23 176 10.1186/s12944-024-02167-0 38851714
Zhou X, Weng X, Xu J, Wang W. Correlation between remnant cholesterol and hyperuricemia in American adults. Lipids Health Dis. 2024;23:176.38851714 10.1186/s12944-024-02167-0
32. Tan MY Weng L Yang ZH Zhu SX Wu S Su JH The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus: recent findings from NHANES 2007–2018 Lipids Health Dis 2024 23 151 10.1186/s12944-024-02143-8 38773578
Tan MY, Weng L, Yang ZH, Zhu SX, Wu S, Su JH. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus: recent findings from NHANES 2007–2018. Lipids Health Dis. 2024;23:151.38773578 10.1186/s12944-024-02143-8
33. Iqbal J Al Qarni A Hawwari A Alghanem AF Ahmed G Metabolic syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism Curr Diabetes Rev 2018 14 427 33 10.2174/1573399813666170705161039 28677496
Iqbal J, Al Qarni A, Hawwari A, Alghanem AF, Ahmed G. Metabolic syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism. Curr Diabetes Rev. 2018;14:427–33.28677496 10.2174/1573399813666170705161039
34. Goodpaster BH Kelley DE Skeletal muscle triglyceride: marker or mediator of obesity-induced insulin resistance in type 2 diabetes mellitus? Curr Diab Rep 2002 2 216 22 10.1007/s11892-002-0086-2 12643176
Goodpaster BH, Kelley DE. Skeletal muscle triglyceride: marker or mediator of obesity-induced insulin resistance in type 2 diabetes mellitus? Curr Diab Rep. 2002;2:216–22.12643176 10.1007/s11892-002-0086-2
35. Toyoki D Shibata S Kuribayashi-Okuma E Xu N Ishizawa K Hosoyamada M Uchida S Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2 Am J Physiol Ren Physiol 2017 313 F826 34 10.1152/ajprenal.00012.2017
Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, Uchida S. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Ren Physiol. 2017;313:F826–34.10.1152/ajprenal.00012.2017
36. Tsunoda S Kamide K Minami J Kawano Y Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent Am J Hypertens 2002 15 697 701 10.1016/S0895-7061(02)02953-9 12160192
Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens. 2002;15:697–701.12160192 10.1016/S0895-7061(02)02953-9
37. Yuan H Hu Y Zhu Y Zhang Y Luo C Li Z Wen T Zhuang W Zou J Hong L Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells Mol Cell Endocrinol 2017 443 138 45 10.1016/j.mce.2016.12.025 28042024
Yuan H, Hu Y, Zhu Y, Zhang Y, Luo C, Li Z, Wen T, Zhuang W, Zou J, Hong L, et al. Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells. Mol Cell Endocrinol. 2017;443:138–45.28042024 10.1016/j.mce.2016.12.025
38. Textor SC Misra S Oderich GS Percutaneous revascularization for ischemic nephropathy: the past, present, and future Kidney Int 2013 83 28 40 10.1038/ki.2012.363 23151953
Textor SC, Misra S, Oderich GS. Percutaneous revascularization for ischemic nephropathy: the past, present, and future. Kidney Int. 2013;83:28–40.23151953 10.1038/ki.2012.363
39. Kawachi K Kataoka H Manabe S Mochizuki T Nitta K Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis Heart Vessels 2019 34 1440 55 10.1007/s00380-019-01375-4 30874893
Kawachi K, Kataoka H, Manabe S, Mochizuki T, Nitta K. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis. Heart Vessels. 2019;34:1440–55.30874893 10.1007/s00380-019-01375-4
40. de Oliveira EP Burini RC High plasma uric acid concentration: causes and consequences Diabetol Metab Syndr 2012 4 12 10.1186/1758-5996-4-12 22475652
de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4:12.22475652 10.1186/1758-5996-4-12
41. Bauer R Brüne B Schmid T Cholesterol metabolism in the regulation of inflammatory responses Front Pharmacol 2023 14 1121819 10.3389/fphar.2023.1121819 36744258
Bauer R, Brüne B, Schmid T. Cholesterol metabolism in the regulation of inflammatory responses. Front Pharmacol. 2023;14:1121819.36744258 10.3389/fphar.2023.1121819
42. Yamamoto S Yancey PG Ikizler TA Jerome WG Kaseda R Cox B Bian A Shintani A Fogo AB Linton MF Dysfunctional high-density lipoprotein in patients on chronic hemodialysis J Am Coll Cardiol 2012 60 2372 9 10.1016/j.jacc.2012.09.013 23141484
Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 2012;60:2372–9.23141484 10.1016/j.jacc.2012.09.013
43. Derosa G Maffioli P Reiner Ž Simental-Mendía LE Sahebkar A Impact of statin therapy on plasma uric acid concentrations: a systematic review and Meta-analysis Drugs 2016 76 947 56 10.1007/s40265-016-0591-2 27260336
Derosa G, Maffioli P, Reiner Ž, Simental-Mendía LE, Sahebkar A. Impact of statin therapy on plasma uric acid concentrations: a systematic review and Meta-analysis. Drugs. 2016;76:947–56.27260336 10.1007/s40265-016-0591-2
44. Doehner W Anker SD Butler J Zannad F Filippatos G Ferreira JP Salsali A Kaempfer C Brueckmann M Pocock SJ Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial Eur Heart J 2022 43 3435 46 10.1093/eurheartj/ehac320 35788657
Doehner W, Anker SD, Butler J, Zannad F, Filippatos G, Ferreira JP, Salsali A, Kaempfer C, Brueckmann M, Pocock SJ, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43:3435–46.35788657 10.1093/eurheartj/ehac320
45. Bragagni A Piani F Borghi C Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes Eur Heart J Suppl 2021 23 E40 4 10.1093/eurheartj/suab094 34650352
Bragagni A, Piani F, Borghi C. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes. Eur Heart J Suppl. 2021;23:E40–4.34650352 10.1093/eurheartj/suab094
46. Li L Zhang Y Zeng C Update on the epidemiology, genetics, and therapeutic options of hyperuricemia Am J Transl Res 2020 12 3167 81 32774692
Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12:3167–81.32774692
